Today: October 21, 2016, 10:11 pm

Belarus pharmaceutical market: Latest market research analysed
The Pharmaceutical Market: Belarus - a new market research report on 2014-03-13 14:17:02
We remain largely pessimistic about the Belarus´ pharmaceutical market development in the short term at least. While the government remains committed to boosting domestic pharmaceutical output over the coming years, with authorities in manufacturing joint venture (JV) discussions with a number of countries, the devalued rouble, high inflation and weak household consumption will continue to constrain both volume and value of medicines consumed in the country. We also note increased political and also economic risks, as the country aligns itself away from the European Union (EU).

Headline Expenditure Projections:

Pharmaceuticals: BYR3,598bn in 2011 (US$692mn) to BYR5,623bn (US$686mn) in 2012; +56.3% in local currency terms and -1.0% in US dollar terms. Forecast upgraded slightly from Q412 on the basis of new macroeconomic data.

Healthcare: BYR12,764bn (US$2.46bn) in 2011 to BYR17,621bn (US$2.15bn) in 2012; +38.1% in local currency terms and -12.5% in US dollar terms. Forecast upgraded slightly from Q412 on the basis of new macroeconomic data.

Medical Devices: BYR2,174bn (US$418mn) in 2011 to BYR3,234bn (US$394mn); +48.8% in local currency terms and -5.7% in US dollar terms. Forecast upgraded slightly from Q412 on the basis of new macroeconomic data.

Risk/Reward Rating

The Pharmaceutical risk/reward rating (RRR) score for Belarus worsened in Q113, largely on account of high levels of inflation and the corresponding weak growth in US dollar terms. The country remains viewed as one of the least attractive pharmaceutical markets in Central and Eastern Europe (CEE), ranking 18th out of 20 countries surveyed regionally. Risks also remain elevated, both on the political and economic fronts.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 499 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.